Description

Arbaclofen Placarbil CAS NO 1314795-11-3 is a prodrug of the active pharmaceutical ingredient (API) R-baclofen, designed to enhance oral bioavailability and central nervous system penetration. This compound is of significant interest for its targeted pharmacological action as a selective GABAB receptor agonist. It is primarily required by pharmaceutical research and development organizations engaged in creating advanced therapeutics for neurological and spasticity disorders. The development of this prodrug represents a strategic approach to improving drug delivery and patient outcomes in CNS-targeted treatments.

Application

• Pharmaceutical Intermediate: Serves as a critical precursor in the synthesis of the active enantiomer, R-baclofen, for final drug product formulation.
• Neurological Research: Used in preclinical and clinical research studies targeting GABAB receptor pathways for conditions like spasticity, chronic pain, and addiction.
• Prodrug Development Studies: Employed as a model compound in research focused on enhancing blood-brain barrier penetration and oral absorption of CNS-active drugs.
• Reference Standard: Utilized as a high-purity analytical standard in quality control laboratories for method development and validation of baclofen-related compounds.
• API Synthesis: A key starting material for contract manufacturing organizations (CMOs) specializing in the production of niche neurological active pharmaceutical ingredients.

Basic Information

Product Name	Arbaclofen Placarbil
CAS No.	1314795-11-3
Molecular Formula	C14H19ClN2O4
Molecular Weight	314.77 g/mol
Synonyms	(R)-Baclofen Prodrug; Arbaclofen placarbil; XP19986; (3R)-4-[[(4-Chlorophenyl)(5-methyl-2-oxo-1,3-oxazol-4-yl)methoxy]methyl]butanoic Acid; STX209; R-Baclofen Ester Prodrug; GABAB Receptor Agonist Prodrug; 4-[[[(4-Chlorophenyl)(5-methyl-2-oxo-3-oxazolyl)methyl]oxy]methyl]butanoic Acid (R)-
EINECS	Contact for details

Quality Control

Our Arbaclofen Placarbil is manufactured under strict quality management systems. Each batch undergoes comprehensive analytical testing, including chiral purity verification, to ensure it meets the stringent requirements for pharmaceutical research and development. Certificates of Analysis (COA) detailing identity, purity, and impurity profiles are provided and can be tailored to support regulatory filings (e.g., FDA, EMA). We adhere to cGMP principles where applicable to guarantee batch-to-batch consistency and traceability.

Storage

Preserve in a tightly closed container, protected from light. Store in a cool, dry place at a controlled room temperature (typically 15-25°C). The product is light-sensitive and should be handled under appropriate conditions to maintain stability. For long-term storage, consider storage under an inert atmosphere to prevent potential degradation.

Specification

Item	Specification
Appearance	White to off-white powder
Identification (IR)	Conforms to structure
Identification (HPLC)	Retention time matches reference standard
Assay (HPLC)	≥98.0%
Chiral Purity (Chiral HPLC)	≥99.0% (R-enantiomer)
Related Substances (HPLC)	Total impurities ≤2.0% Any single unknown impurity ≤0.5%
Residual Solvents (GC)	Complies with ICH Q3C guidelines
Loss on Drying	≤0.5%

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.